TB-500

Description

What Is TB‑500?

TB‑500 is a synthetic peptide fragment derived from the naturally occurring protein Thymosin Beta‑4. It was designed to replicate the biological activity of the parent molecule while offering improved stability and bioavailability. TB‑500 has been studied for its regenerative, anti‑inflammatory, and cytoprotective properties, making it relevant in tissue repair and recovery research.

Mechanism of Action

TB‑500 exerts its effects by binding to actin, a key cytoskeletal protein, thereby modulating cell migration and angiogenesis. This activity enhances wound healing, promotes new blood vessel formation, and supports tissue remodeling. It also reduces inflammatory cytokine activity, contributing to faster recovery and reduced tissue damage. TB‑500’s ability to influence cellular motility and differentiation positions it as a candidate for regenerative medicine and musculoskeletal repair.

Research & Clinical Data

Preclinical studies highlight TB‑500’s efficacy in accelerating healing of muscle, tendon, and ligament injuries. It has been investigated for cardiovascular protection, corneal repair, and recovery from ischemic injury. While anecdotal reports suggest benefits in athletic recovery, regulatory approval has not been granted, and TB‑500 remains investigational. Side effects are generally mild, including injection site irritation, though long‑term safety data are limited.

Purity & Quality

Reference‑grade peptide material. Certificate of Analysis available per batch. Regulatory status: investigational, not FDA‑ or EMA‑approved.

Classification & Handling Class: Synthetic peptide fragment | Source: Thymosin Beta‑4 analog | Administration: Subcutaneous or intramuscular injection (investigational) | Storage: 2–8°C refrigerated, protect from light | Regulatory: Not FDA/EMA approved